Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Ames, Iowa
This trial looks at two different doses of imatinib mesylate and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.